Brain Wealthy
    What's Hot

    Non-compete agreements should be banned, says President Biden

    February 8, 2023

    Microsoft’s AI-Powered Bing Comes to Google’s Bard-Powered Search

    February 7, 2023

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»Tevogen Bio Appoints Cell Therapy Expert Dr. Dolores Grosso as Global Head of Clinical Development to Address Portfolio Expansion
    Neurology

    Tevogen Bio Appoints Cell Therapy Expert Dr. Dolores Grosso as Global Head of Clinical Development to Address Portfolio Expansion

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 4, 2023No Comments5 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    News and research before it hits the news on CNBC and more. Claim your 1 week free trial Street Insider Premium Here.


    • Dr. Grosso will develop and execute the company’s expanding clinical trial program.

    • Tevogen’s cell therapy research pipeline focuses on virology, neurology, and oncology.

    • Tevogen is reported as the most valuable tech startup in 2022.

    WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in virology, neurology and oncology, today announced the appointment of Dr. Appointed and the company’s expanding clinical trial portfolio.

    This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20230104005931/en/

    Dr. Dolores Grosso, Global Head of Clinical Development, Tevogen Bio (Photo: Business Wire)

    Dr. Dolores Grosso, Global Head of Clinical Development, Tevogen Bio (Photo: Business Wire)

    Dr. Grosso has been in healthcare for over 40 years. During his first 15 years he worked as a critical care nurse at Thomas Jefferson University in Philadelphia. He earned his Master of Science degree in 1986 and his Postmaster’s Nurse Practitioner degree in 1995, both from the University of Pennsylvania in Critical Care Nursing. In 1996, she participated in a blood and bone marrow transplant program as a nurse at Thomas Herr Jefferson University.

    Over the next 25 years, Dr. Grosso expanded his career in cell therapy research under the guidance of eminent oncologist Professor Neal Flomenberg. Jefferson University. Later that year, she was appointed to the faculty of the Jefferson School of Medicine, eventually earning her the position of Associate Professor of Research in early 2022. Dr. Grosso has authored over 20 of her investigator-initiated research protocols, including multiple first and final author publications. She has served as research mentor to numerous Physician Fellows, including several participating in the Master of Pharmacology program at Jefferson University. In 2021, she will receive a prestigious clinical research award from her Thomas Kimmel Cancer Center at Jefferson University in Sydney in recognition of her prolific research work and her contributions to the cancer center’s clinical research efforts. Received the Excellence Award.

    Dr Grosso said: treatment of illness. ”

    “Since our founding in 2020, our advanced science and business model have made us one of the most successful start-up biotech companies. As the founder of Tevogen, Dr. Grosso’s unique experience and unwavering We are excited to welcome Passion to our leadership team.

    About Tevogen’s Next Generation Precision T Cell Platform

    Tevogen’s next-generation precision T-cell platform is designed to increase immunological specificity to eliminate malignant and virus-infected cells while keeping healthy cells intact. Multiple targets are selected in advance with the goal of overcoming the mutational capacity of cancer cells and viruses. Otherwise, it can escape immunological targets.

    Tevogen is exploring the technology’s potential to overcome key barriers to widespread application of personalized T-cell therapy, including potency, purity, large-scale production, and patient pairing, without the limitations of current approaches . Tevogen’s goal is to open up vast and unprecedented possibilities for developing personalized immunotherapies for large patient populations affected by common cancers and viral infections.

    Tevogen has announced the completion of patient enrollment in a proof-of-concept clinical trial of its lead product, TVGN-489. It is in ambulatory acute-risk COVID-19 patients with no observed dose-limiting toxicities or serious treatment-related adverse events. Any patient at any dose level.

    TVGN-489 is a non-genetically engineered off-the-shelf allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the SARS-CoV-2 genome.

    About Tevogen Bio

    Tevogen Bio is driven by a team of experienced industry leaders and distinguished scientists with experience in drug development and global product launches. Tevogen management believes that accessible personalized immunotherapy is the next frontier in medicine and that disruptive business models are needed to sustain medical innovation in a post-pandemic world.

    Forward-Looking Statements

    This press release contains certain forward-looking statements regarding Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are based on known and unknown risks, delays and uncertainties and statements regarding actual results, performance or forward-looking statements thereof. results, performance or other results that are materially different from those implied by Forward-looking statements are defined as “may,” “will,” “should,” “intend,” “expect,” “believe,” “could,” may be identified by terms such as, or the negation or equivalent thereof. Terms and other words and expressions that refer to future events, conditions, or circumstances. Forward-looking statements in which the Company expresses expectations or beliefs regarding future results do not provide any assurance that those statements, expectations or beliefs will be achieved. Various factors may cause differences between our forecasts and actual results. For example: Uncertainties inherent in the conduct, costs and completion of preclinical and clinical trials. risks associated with regulatory review, approval and commercial development; Risks Associated with Intellectual Property Protection. risks associated with matters that may affect our future financial results, including the commercial potential, sales and pricing of our products; We undertake no obligation to update any forward-looking statements or information in this release, or to provide additional information, except as required by law and expressly disclaims all liability and We make no representations or warranties in connection with the release. I respect the omission from there.

    View source version at businesswire.com: https://www.businesswire.com/news/home/20230104005931/en/

    Tevogen Communications

    T: 1 877 TEVOGEN, Ext 701

    [email protected]

    Source: Tevogen Bio





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleBiohaven launched with neurological target overweight at JP Morgan (NYSE:BHVN)
    Next Article Can a combination of diet and medication reduce seizures? — Science Daily
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.